BR112018007399A2 - composição, método de tratamento, kit de partes e forma de dosagem - Google Patents

composição, método de tratamento, kit de partes e forma de dosagem

Info

Publication number
BR112018007399A2
BR112018007399A2 BR112018007399A BR112018007399A BR112018007399A2 BR 112018007399 A2 BR112018007399 A2 BR 112018007399A2 BR 112018007399 A BR112018007399 A BR 112018007399A BR 112018007399 A BR112018007399 A BR 112018007399A BR 112018007399 A2 BR112018007399 A2 BR 112018007399A2
Authority
BR
Brazil
Prior art keywords
composition
treatment
dosage form
part kit
kit
Prior art date
Application number
BR112018007399A
Other languages
English (en)
Portuguese (pt)
Inventor
Mayo John
Wolf-Garraway Richard
Henry William
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of BR112018007399A2 publication Critical patent/BR112018007399A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018007399A 2015-10-14 2016-10-14 composição, método de tratamento, kit de partes e forma de dosagem BR112018007399A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Publications (1)

Publication Number Publication Date
BR112018007399A2 true BR112018007399A2 (pt) 2018-10-16

Family

ID=55131025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007399A BR112018007399A2 (pt) 2015-10-14 2016-10-14 composição, método de tratamento, kit de partes e forma de dosagem

Country Status (15)

Country Link
US (3) US20190192664A1 (cg-RX-API-DMAC10.html)
EP (1) EP3362039A1 (cg-RX-API-DMAC10.html)
JP (1) JP7160678B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180067616A (cg-RX-API-DMAC10.html)
CN (1) CN108472246A (cg-RX-API-DMAC10.html)
AU (1) AU2016336929B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018007399A2 (cg-RX-API-DMAC10.html)
CA (1) CA3036111C (cg-RX-API-DMAC10.html)
EA (1) EA201890703A1 (cg-RX-API-DMAC10.html)
GB (1) GB201518172D0 (cg-RX-API-DMAC10.html)
HK (1) HK1256814A1 (cg-RX-API-DMAC10.html)
IL (1) IL258567B2 (cg-RX-API-DMAC10.html)
MX (1) MX391574B (cg-RX-API-DMAC10.html)
SG (2) SG11201802956RA (cg-RX-API-DMAC10.html)
WO (1) WO2017064276A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122516130A (zh) * 2019-11-07 2026-08-07 伊利诺伊大学评议会 治疗脓毒症、动脉粥样硬化、血栓形成、中风、心脏病发作和炎症的肽和方法
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU7384994A (en) 1993-08-06 1995-02-28 Opperbas Holding B.V. A method for high loading of vesicles with biopolymeric substances
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
PT1198490E (pt) 1999-07-14 2006-06-30 Alza Corp Lipopolimeros neutros e composicoes liposomais que contem os mesmos
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
PT1633440E (pt) 2003-04-15 2008-08-25 Opperbas Holding Bv Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais
BRPI0612843A2 (pt) 2005-06-29 2010-11-30 The Research Foundation Of State University Of New York composição farmacêutica, métodos para fabricar a composição, e, uso de uma formulação
JP2012528846A (ja) 2009-06-03 2012-11-15 マヨ、ジョン、チャールズ 深部組織の痛みを治療するための製剤
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
HK1200695A1 (en) 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
ES2887254T3 (es) * 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos

Also Published As

Publication number Publication date
MX2018004445A (es) 2018-08-14
JP2018535952A (ja) 2018-12-06
CA3036111A1 (en) 2017-04-20
JP7160678B2 (ja) 2022-10-25
US20190192664A1 (en) 2019-06-27
HK1256814A1 (zh) 2019-10-04
EP3362039A1 (en) 2018-08-22
AU2016336929B2 (en) 2022-09-29
EA201890703A1 (ru) 2018-11-30
KR20180067616A (ko) 2018-06-20
CA3036111C (en) 2023-06-06
MX391574B (es) 2025-03-21
IL258567A (en) 2018-05-31
AU2016336929A1 (en) 2018-05-10
IL258567B1 (en) 2025-04-01
IL258567B2 (en) 2025-08-01
SG10202010711UA (en) 2020-12-30
US20250170244A1 (en) 2025-05-29
CN108472246A (zh) 2018-08-31
WO2017064276A1 (en) 2017-04-20
SG11201802956RA (en) 2018-05-30
US20210093721A1 (en) 2021-04-01
GB201518172D0 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
BR112018003877A2 (pt) “composição farmacêutica, método para reduzir a gordura subcutânea, método para a redução de peso corporal e uso de uma composição farmacêutica”
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
MX378579B (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
BR112018007560A2 (pt) composição cosmética tendo bactérias probióticas
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112014027653A2 (pt) formulações para a liberação dos ingredientes ativos
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
MX380429B (es) Composición para tratar lesiones tisulares.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX391574B (es) Partículas coloidales para su uso en medicina.
MX2019000717A (es) Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos.
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]